Phase 2 Obesity Trial, Recruiting (NCT06345560)

Phase 2 Obesity Trial, Recruiting NCT06345560 Sponsor: Chulalongkorn University Condition: Obesity

Printed from Voxsanity (voxsanity.com.au) — NCT06345560 — Data sourced from ClinicalTrials.gov. Verify directly with the trial site before attending. Not medical advice.

Back to Obesity

Who may be able to join

AI generated eligibility summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI

Who might be able to join this trial:

Thai women between 18 and 45 years old who are classified as obese and have an upcoming bariatric (weight-loss) surgery appointment at Chulalongkorn Hospital
People who need a form of contraception (birth control)
People who are able to use non-hormonal birth control methods during the study period
People who are willing to give their consent to take part

Who may not be able to join:

People who are currently pregnant or who have given birth within the last 3 months
People who have been breastfeeding within the last 6 months
People who have used the injectable contraceptive DMPA (a hormonal birth control injection) within the last 12 months
People who have used any other type of hormonal birth control pill within the last 4 weeks
People who have had both ovaries removed or have had their uterus removed
People with a suspected ovarian tumour or an abnormal ovarian cyst
People who smoke cigarettes regularly
People who have medical reasons that make the medication Drospirenone (a type of hormonal drug) unsuitable for them

Important: Always verify eligibility with the trial site directly before applying.

Based on publicly available eligibility criteria from ClinicalTrials.gov. Verify directly with the trial site before acting. This is not medical advice.

This is a simplified plain English summary of the eligibility criteria. Full criteria are set by the trial investigators and may include additional requirements not shown here. Never self-exclude from a trial based on this summary. Contact the trial site directly to confirm your eligibility.

Last synced 19 July 2026

Phase 2: approximately ~30% of drugs entering this phase reach regulatory approval, based on published industry-wide historical data. This is not specific to this trial.

Phase success rates shown are historical industry-wide averages based on published data. They are not a prediction for this specific trial or your individual situation.

Contact this trial

Principal Investigator: Punyawee Utaipatanacheep, Chulalongkorn University

Phone: +668-7515-4003

Contact details sourced from ClinicalTrials.gov. Verify directly with the trial site before attending.

GP referral letter

Print a one-page summary to share with your doctor.

Voxsanity

Clinical trials and treatments, explained plainly · voxsanity.com.au

Date:

To: My Doctor

Re: Clinical trial enquiry

I am writing to enquire about the following clinical trial which may be relevant to my care:

Trial: NCT06345560

Sponsor: Chulalongkorn University

Phase: Phase 2

Status: Recruiting

Condition: Obesity

Trial contact: +668-7515-4003

More information: https://clinicaltrials.gov/study/NCT06345560

Eligibility summary (AI generated)

Written by an AI model from ClinicalTrials.gov eligibility criteria and checked on a sample basis. Please confirm against the original criteria.

Who might be able to join this trial:

Thai women between 18 and 45 years old who are classified as obese and have an upcoming bariatric (weight-loss) surgery appointment at Chulalongkorn Hospital
People who need a form of contraception (birth control)
People who are able to use non-hormonal birth control methods during the study period
People who are willing to give their consent to take part

Who may not be able to join:

People who are currently pregnant or who have given birth within the last 3 months
People who have been breastfeeding within the last 6 months
People who have used the injectable contraceptive DMPA (a hormonal birth control injection) within the last 12 months
People who have used any other type of hormonal birth control pill within the last 4 weeks
People who have had both ovaries removed or have had their uterus removed
People with a suspected ovarian tumour or an abnormal ovarian cyst
People who smoke cigarettes regularly
People who have medical reasons that make the medication Drospirenone (a type of hormonal drug) unsuitable for them

Important: Always verify eligibility with the trial site directly before applying.

Access in Australia: A treatment being studied in a clinical trial is generally not yet listed on the PBS. Where a medicine is not approved or not available through a trial, the TGA Special Access Scheme may allow a doctor to access unapproved therapeutic goods for individual patients. See voxsanity.com.au/sas-navigator/ for a plain English explainer.

This information was sourced from ClinicalTrials.gov via Voxsanity (data last synced 19 July 2026). It is not medical advice. Please verify the trial's current status directly with the trial site before acting.

Trial details

Status

Recruiting

Phase

Phase 2

Sponsor

Chulalongkorn University

Registry

ClinicalTrials.gov

Start date

18 April 2024

Est. completion

1 July 2026

Where this trial is recruiting

🇹🇭 Thailand

Primary endpoints

Plasma concentration versus Time of Drospirenone

Can't join this trial?

Expanded access pathways

If this trial is not available to you, other access pathways may exist. In Australia, the TGA Special Access Scheme allows access to unapproved therapeutic goods for individual patients.

TGA Special Access Scheme information

Find other recruiting trials on ClinicalTrials.gov

Data last synced from ClinicalTrials.gov: 19 July 2026. Trial status can change. Always verify current status directly with the trial site before making any decision.

Trial recruitment status can change without notice between our nightly data updates. Always contact the trial site directly to confirm current recruitment status before making any decisions or travel arrangements.

View original record on ClinicalTrials.gov